Oncotarget helps resolve controversy over the role of FOXO genes in breast cancer

Cancer is caused by a change in the genes the regulate cell death. In theory, a cancer cell could live forever, although the tendency of the disease to kill the patient if unchecked prevents this from happening. No one knows what causes the cells to mutate, although scientists know that a genetic factor makes it more likely that some people will develop breast caner. The family involvement has been known, and both women and men with a history of breast cancer in their family can develop the disease. Researchers at Oncotarget continue to work out the role of four genes that belong to the FOX group, according to the online journal Research Gate.

Four of the FOXO genes – 1, 3, 4 and 6 – are known to play a role in carcinogenesis and apoptosis of breast cancer. The state of research so far has researchers arguing over which process on which the genes have impact. A few braver researchers argue that the genes can effect both, depending on how they are expressed in an individual. Oncotarget researchers hope further researcher will resolve the debate and the mystery surrounding the functions of these genes. Check Oncotarget journal at scimagojr.com

Someone who has been newly diagnosed with breast cancer may come upon these genes and their disputed function eventually, but the best course of action is still routine screenings to detect the formation of the disease early. This can be done through self examination and regular mammograms. Regular mammograms should start after a woman turns 40, and they should be conducted every two years. Self-examinations should be performed on a more regular basis. Every two months is generally recommended, but this can be done less or more often as desired.

Visit: https://www.facebook.com/Oncotarget/

Dr. Mark Holterman and His Medical Achievements

Dr. Mark Holterman received his bachelor degree from Yale and received his MD and PhD in medicine and immunology from the University of Virginia. He completed a general surgery residency at the University of Virginia Health Sciences and a pediatric surgery fellowship with the Children’s Hospital and Medical Center at the University of Washington. Dr. Holterman is affiliated with the Advocate Illinois Masonic Medical Center, the Loyola University Medical Center, and St Alexius Medical Center. Read more about Dr. Mark Holterman at Dial Dish.

During his past 29 years of experience as a physician, Dr. Mark Holterman has received the American’s Top Doctors award in 2008, 2010, 2011, 2012, 2013, 2014, 2015, and 2017. He is currently a full professor of surgery and pediatrics at the University of Illinois College of Medicine, where he has been for the last six years. He is also a member of the American College of Surgeons and the American Academy of Pediatrics. Additionally, Dr. Holterman pursues research in the areas of regenerative medicine, stem cell therapies, obesity, and cancer treatments. Learn more about Dr. Mark Holterman’s profile at healthgrove.com.

Dr. Mark Holterman is a member of several professional organizations, including the American Diabetes Association (ADA). ADA focuses on research advancements aimed at curing or preventing the occurrence of diabetes. ADA also collaborates with many organizations, including the Mental Health Provider Diabetes Education Program, a program that supports and educates mental health professionals as they provide holistic care for individuals contending with diabetes management. As part of their continuing education program, practitioners will also complete a seminar and brief online course. Once finished, members are listed on the ADA website, which can be viewed by patients seeking treatment. Dr. Mark Holterman was also heavily involved in establishing The Hannah Sunshine Foundation, an organization that evaluates the use of cellular and regenerative therapies for rare pediatric diseases. The program was inspired by the cases of several children, including a young woman afflicted with systemic juvenile idiopathic arthritis. The condition is rare and has no known cure, but the disease can be managed with the aim of achieving permanent remission.

Read: https://ideamensch.com/mark-holterman/